451 related articles for article (PubMed ID: 35458460)
21. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes.
Chiba S; Kong H; Neumann G; Kawaoka Y
mBio; 2023 Aug; 14(4):e0062223. PubMed ID: 37466314
[TBL] [Abstract][Full Text] [Related]
22. Production of Neuraminidase Virus Like Particles by Stably Transformed Insect Cells: A Simple Process for NA-Based Influenza Vaccine Development.
Khanefard N; Sapavee S; Akeprathumchai S; Mekvichitsaeng P; Poomputsa K
Mol Biotechnol; 2022 Dec; 64(12):1409-1418. PubMed ID: 35704162
[TBL] [Abstract][Full Text] [Related]
23. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
Kamlangdee A; Kingstad-Bakke B; Osorio JE
J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
[TBL] [Abstract][Full Text] [Related]
24. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
25. Site-Specific Glycan-Masking/Unmasking Hemagglutinin Antigen Design to Elicit Broadly Neutralizing and Stem-Binding Antibodies Against Highly Pathogenic Avian Influenza H5N1 Virus Infections.
Chen TH; Yang YL; Jan JT; Chen CC; Wu SC
Front Immunol; 2021; 12():692700. PubMed ID: 34335603
[TBL] [Abstract][Full Text] [Related]
26. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
[TBL] [Abstract][Full Text] [Related]
27. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.
Carreño JM; Strohmeier S; Kirkpatrick Roubidoux E; Hai R; Palese P; Krammer F
mBio; 2020 Dec; 11(6):. PubMed ID: 33323511
[TBL] [Abstract][Full Text] [Related]
28. Development and biochemical characterization of the monoclonal antibodies for specific detection of the emerging H5N8 and H5Nx avian influenza virus hemagglutinins.
Cheng YC; Chang SC
Appl Microbiol Biotechnol; 2021 Jan; 105(1):235-245. PubMed ID: 33245391
[TBL] [Abstract][Full Text] [Related]
29. Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine).
Gambaryan AS; Lomakina NF; Boravleva EY; Kropotkina EA; Mashin VV; Krasilnikov IV; Klimov AI; Rudenko LG
Influenza Other Respir Viruses; 2012 May; 6(3):188-95. PubMed ID: 21951678
[TBL] [Abstract][Full Text] [Related]
30. Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
Kim KH; Jung YJ; Lee Y; Park BR; Oh J; Lee YN; Kim MC; Jeeva S; Kang SM
Virology; 2020 Nov; 550():51-60. PubMed ID: 32882637
[TBL] [Abstract][Full Text] [Related]
31. Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.
Chen YQ; Lan LY; Huang M; Henry C; Wilson PC
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518651
[TBL] [Abstract][Full Text] [Related]
32. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
[TBL] [Abstract][Full Text] [Related]
33. Hemagglutinin stalk domain from H5N1 strain as a potentially universal antigen.
Uranowska K; Tyborowska J; Jurek A; Szewczyk B; Gromadzka B
Acta Biochim Pol; 2014; 61(3):541-50. PubMed ID: 25210720
[TBL] [Abstract][Full Text] [Related]
34. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
[TBL] [Abstract][Full Text] [Related]
36. N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies.
Huang Y; Owino SO; Crevar CJ; Carter DM; Ross TM
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852790
[TBL] [Abstract][Full Text] [Related]
37. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
[TBL] [Abstract][Full Text] [Related]
38. Hemagglutinin amino acids related to receptor specificity could affect the protection efficacy of H5N1 and H7N9 avian influenza virus vaccines in mice.
Xu L; Bao L; Lau SY; Wu WL; Yuan J; Gu S; Li F; Lv Q; Xu Y; Pushko P; Chen H; Qin C
Vaccine; 2016 May; 34(23):2627-33. PubMed ID: 27083426
[TBL] [Abstract][Full Text] [Related]
39. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.
Zost SJ; Wu NC; Hensley SE; Wilson IA
J Infect Dis; 2019 Apr; 219(Suppl_1):S38-S45. PubMed ID: 30535315
[TBL] [Abstract][Full Text] [Related]
40. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
